A share price of Sutro Biopharma Inc [STRO] is currently trading at $0.90, up 2.44%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The STRO shares have gain 10.38% over the last week, with a monthly amount glided 62.90%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sutro Biopharma Inc [NASDAQ: STRO] stock has seen the most recent analyst activity on March 17, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, Wedbush downgraded its rating to Neutral on March 14, 2025, and dropped its price target to $2. On March 14, 2025, downgrade downgraded it’s rating to Mkt Perform. BofA Securities downgraded its rating to a Underperform and decreased its price target to $1 on March 14, 2025. BofA Securities initiated its recommendation with a Buy and recommended $12 as its price target on May 08, 2024. Deutsche Bank started tracking with a Buy rating for this stock on November 09, 2023, and assigned it a price target of $12. In a note dated October 06, 2023, Oppenheimer initiated an Outperform rating and provided a target price of $10 on this stock.
Sutro Biopharma Inc experienced fluctuations in its stock price throughout the past year between $0.52 and $5.17. Currently, Wall Street analysts expect the stock to reach $2 within the next 12 months. Sutro Biopharma Inc [NASDAQ: STRO] shares were valued at $0.90 at the most recent close of the market. An investor can expect a potential return of 122.22% based on the average STRO price forecast.
Analyzing the STRO fundamentals
Trailing Twelve Months sales for Sutro Biopharma Inc [NASDAQ:STRO] were 66.43M which represents 33.76% growth. Gross Profit Margin for this corporation currently stands at 0.04% with Operating Profit Margin at -3.77%, Pretax Profit Margin comes in at -3.66%, and Net Profit Margin reading is -3.69%. To continue investigating profitability, this company’s Return on Assets is posted at -0.76, Equity is -3.48 and Total Capital is -1.33. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.83.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Sutro Biopharma Inc [NASDAQ:STRO] is 2.16. As well, the Quick Ratio is 2.16, while the Cash Ratio is 0.8. Considering the valuation of this stock, the price to sales ratio is 1.14.
